At the time of writing, Olema Pharmaceuticals Inc [OLMA] stock is trading at $8.72, down -0.80%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The OLMA shares have gain 5.31% over the last week, with a monthly amount drifted -8.60%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Olema Pharmaceuticals Inc [NASDAQ: OLMA] stock has seen the most recent analyst activity on October 08, 2025, when Guggenheim initiated its Buy rating and assigned the stock a price target of $20. Previously, Citigroup reaffirmed its Buy rating on August 12, 2025, and elevated its price target to $21. On April 02, 2024, Goldman initiated with a Buy rating and assigned a price target of $24 on the stock. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $20 on January 30, 2024. Oppenheimer initiated its recommendation with a Outperform and recommended $21 as its price target on July 21, 2023. CapitalOne started tracking with a Overweight rating for this stock on May 05, 2023, and assigned it a price target of $16. In a note dated February 22, 2023, Credit Suisse initiated an Outperform rating and provided a target price of $12 on this stock.
For the past year, the stock price of Olema Pharmaceuticals Inc fluctuated between $2.86 and $13.51. Currently, Wall Street analysts expect the stock to reach $24 within the next 12 months. Olema Pharmaceuticals Inc [NASDAQ: OLMA] shares were valued at $8.72 at the most recent close of the market. An investor can expect a potential return of 175.23% based on the average OLMA price forecast.
Analyzing the OLMA fundamentals
Gross Profit Margin for this corporation currently stands at -0.11% with Operating Profit Margin at -431.66%, Pretax Profit Margin comes in at -390.92%, and Net Profit Margin reading is -390.92%. To continue investigating profitability, this company’s Return on Assets is posted at -0.37, Equity is -0.43 and Total Capital is -0.45. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.47 points at the first support level, and at 8.22 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.01, and for the 2nd resistance point, it is at 9.30.
Ratios To Look Out For
It is important to note that Olema Pharmaceuticals Inc [NASDAQ:OLMA] has a current ratio of 11.09. Further, the Quick Ratio stands at 11.09, while the Cash Ratio is 1.58.
Transactions by insiders
Recent insider trading involved Harmon Cyrus, Director, that happened on Sep 18 ’25 when 10000.0 shares were sold. Director, Harmon Cyrus completed a deal on Sep 16 ’25 to sell 10000.0 shares. Meanwhile, Director Harmon Cyrus sold 3086.0 shares on Sep 18 ’25.
